European Journal of Clinical Pharmacology

, Volume 66, Issue 11, pp 1109–1117 | Cite as

The role of CYP2D6 and ABCB1 pharmacogenetics in drug-naïve patients with first-episode schizophrenia treated with risperidone

  • Nikolina JovanovićEmail author
  • Nada Božina
  • Mila Lovrić
  • Vesna Medved
  • Miro Jakovljević
  • Alma Mihaljević Peleš



To evaluate the role of cytochrome 450 2D6 (CYP2D6) and ABCB1 variants on plasma risperidone concentrations and treatment response in 83 drug-naive patients experiencing a first episode of psychosis.


All patients were treated with risperidone for 8 weeks. The CYP2D6 genotyping was performed by allele-specific PCR–restriction fragment length polymorphism analysis (for alleles *3,*4,*6) and long-distance PCR (for duplications and allele *5), while real-time PCR analysis was used for the ABCB1 G2677T/A and C3435T variants. Plasma concentrations of risperidone and 9-OH risperidone were measured by high-performance liquid chromatography.


The number of patients with the CYP2D6 wild type (wt)/wt, wt/mutation (mut) and mut/mut genotype was 43, 32 and 8, respectively. The number of patients with the ABCB1 2677G/G, G/T and T/T variants was 29, 42 and 12, respectively; those with the 3435CC, C/T and T/T variants was 25, 37 and 21, respectively. The CYP2D6 genotype had a strong effect on the steady-state dose-corrected plasma levels (C/D) of risperidone, its 9-OH metabolite and the active moiety, while the ABCB1 2677 T/T and 3435 T/T genotypes has similarly strong effects on the active moiety C/D. The CYP2D6 poor metabolizers had a significantly higher risperidone C/D and active moiety C/D and lower 9-OH risperidone C/D. The ABCB1 3435 T allele and the ABCB1 2667 T-3435 T haplotype carriers were more frequent among subjects without extrapyramidal syndromes. Patients showed significant improvements in positive and general symptoms, but not in negative symptoms. These changes were not related to variations in genetic and drug concentration data.


Our findings suggest that CYP2D6 and ABCB1 G2677T and C3435T may be useful determinants of risperidone plasma concentrations, but the clinical implications of these associations in relation to treatment response and side-effects remain unclear.


Risperidone 9-hydroxirisperidone CYP2D6 ABCB1 Schizophrenia 


  1. 1.
    Arranz MJ, de Leon J (2007) Pharmacogenetics and pharmacogenomics of schizophrenia: a review of last decade of research. Mol Psychiatry 12:707–747CrossRefPubMedGoogle Scholar
  2. 2.
    Aravagiri M, Marder SR, Wirshing D, Wirshing WC (1998) Plasma concentrations of risperidone and its 9-hydroxy metabolite and their relationship to dose in schizophrenic patients: simultaneous determination by a high performance liquid chromatography with electrochemical detection. Pharmacopsychiatry 31:102–109CrossRefPubMedGoogle Scholar
  3. 3.
    Fang J, Bourin M, Baker GB (1999) Metabolism of risperidone to 9-hydroxyrisperidone by human cytochrome P450 2D6 and 3A4. Naunyn-Schmiederberg’s Arch Pharmacol 359:147–151CrossRefGoogle Scholar
  4. 4.
    Yasui-Furukori N, Hidestrand M, Spina E, Facciolà G, Scordo MG, Tybring G (2001) Different enantioselective 9-hydroxylation of risperidone by the two human CYP2D6 and CYP3A4 enzymes. Drug Metab Dispos 29:1263–1268PubMedGoogle Scholar
  5. 5.
    Zhou SF (2009) Polymorphism of human cytochrome P450 2D6 and its clinical significance: part I. Clin Pharmacokinet 48:689–723CrossRefPubMedGoogle Scholar
  6. 6.
    Marzolini C, Paus E, Buclin T, Kim RB (2004) Polymorphisms in human MDR1 (Pglycoprotein): recent advances and clinical relevance. Clin Pharmacol Ther 75:13–33CrossRefPubMedGoogle Scholar
  7. 7.
    Boulton DW, DeVane CL, Liston HL, Markowitz JS (2002) In vitro P-glycoprotein affinity for atypical and conventional antipsychotics. Life Sci 71:163–169CrossRefPubMedGoogle Scholar
  8. 8.
    Hoffmeyer S, Burk O, von Richter O, Arnold HP, Brockmoller J, Johne A, Cascorbi I, Gerloff T, Roots I, Eichelbaum M, Brinkmann U (2000) Functional polymorphisms of the human multidrug-resistance gene. multiple sequence variations and correlation of one allele with P-glycoprotein expression and activity in vivo. Proc Natl Acad Sci USA 97:3473–3478CrossRefPubMedGoogle Scholar
  9. 9.
    Scordo MG, Spina E, Facciolà G, Avenoso A, Johansson I, Dahl ML (1999) Cytochrome P450 2D6 genotype and steady state plasma levels of risperidone and 9-hydroxyrisperidone. Psychopharmacology 147:300–305CrossRefPubMedGoogle Scholar
  10. 10.
    Gunes A, Spina E, Dahl ML, Scordo MG (2008) ABCB1 polymorphisms influence steady-state plasma levels of 9-hydroxyrisperidone and risperidone active moiety. Ther Drug Monit 30:628–633CrossRefPubMedGoogle Scholar
  11. 11.
    Yasui-Furukori N, Mihara K, Takahata T, Suzuki A, Nakagami T, De Vries R, Tateishi T, Kondo T, Kaneko S (2004) Effects of various factors on steady-state plasma concentrations of risperidone and 9-hydroxyrisperidone: lack of impact of MDR-1 genotypes. Br J Clin Pharmacol 57:569–575CrossRefPubMedGoogle Scholar
  12. 12.
    World Health Organization (WHO) (1990) International classification of Disease, 10th edn (ICD-10). WHO, GenevaGoogle Scholar
  13. 13.
    Kay SR, Fiszbein A, Opler LA (1988) Positive and Negative Symptom Scale (PANSS) for schizophrenia. Schizophr Bull 13:21–76Google Scholar
  14. 14.
    Simpson GN, Angus JWS (1970) A rating scale for extrapyramidal side effects. Acta Psychiatr Scand 212:11–19CrossRefGoogle Scholar
  15. 15.
    Stüven T, Griese EU, Kroemer HK, Eichelbaum M, Zanger UM (1996) Rapid detection of CYP2D6 null alleles by long distance and multiplex-polymerase chain reaction. Pharmacogenetics 6:417–421CrossRefPubMedGoogle Scholar
  16. 16.
    Arjomand-Nahad F, Diefenbach K, Landt O, Gaikovitch E, Roots I (2004) Genotyping of the triallelic variant G2677T/A in MDR1 using LightCycler with locked-nucleic-acid-modified hybridization probes. Anal Biochem 334:201–203CrossRefPubMedGoogle Scholar
  17. 17.
    Oselin K, Gerloff T, Mrozikiewicz PM, Pähkla R, Roots I (2003) MDR1 polymorphisms G2677T in exon 21 and C3435T in exon 26 fail to affect rhodamine 123 efflux in peripheral blood lymphocytes. Fundam Clin Pharmacol 17:463–469CrossRefPubMedGoogle Scholar
  18. 18.
    von Ahsen N, Richter M, Grupp C, Ringe B, Oellerich M, Armstrong VW (2001) No influence of the MDR-1 C3435T polymorphism or a CYP3A4 promoter polymorphism (CYP3A4-V allele) on dose-adjusted cyclosporin A trough concentrations or rejection incidence in stable renal transplant recipients. Clin Chem 47:1048–1052Google Scholar
  19. 19.
    Bozina N, Jovanovic N, Lovric M, Medved V (2008) Clinical significance of a CYP2D6 poor metabolizer: a case report of a patient with schizophrenia on risperidone treatment. Ther Drug Monit 30:748–751CrossRefPubMedGoogle Scholar
  20. 20.
    Roh HK, Kim CE, Chung WG, Park CS, Svensson JO, Bertilsson L (2001) Risperidone metabolism in relation to CYP2D6*10 allele in Korean schizophrenic patients. Eur J Clin Pharmacol 57:671–675CrossRefPubMedGoogle Scholar
  21. 21.
    Bozina N, Granić P, Lalić Z, Tramisak I, Lovrić M, Stavljenić-Rukavina A (2003) Genetic polymorphisms of cytochromes P450: CYP2C9, CYP2C19, and CYP2D6 in Croatian population. Croat Med J 44:425–428PubMedGoogle Scholar
  22. 22.
    de Leon J, Susce MT, Pan RM, Fairchild M, Koch WH, Wedlund PJ (2005) The CYP2D6 poor metabolizer phenotype may be associated with risperidone adverse drug reactions and discontinuation. J Clin Psychiatry 66:15–27CrossRefPubMedGoogle Scholar
  23. 23.
    Ito S, Ieiri I, Tanabe M, Suzuki A, Higuchi S, Otsubo K (2001) Polymorphism of the ABC transporter genes, MDR1, MRP1 and MRP2/cMOAT, in healthy Japanese subjects. Pharmacogenetics 11:175–184CrossRefPubMedGoogle Scholar
  24. 24.
    Yoshimura R, Ueda N, Nakamura J (2001) Possible relationship between combined plasma concentrations of risperidone plus 9-hydroxyrisperidone and extrapyramidal symptoms. Preliminary study. Neuropsychobiology 44:129–133CrossRefPubMedGoogle Scholar
  25. 25.
    Spina E, Avenoso A, Facciola G, Salemi M, Scordo MG, Ancione M, Madia AG, Perucca E (2001) Relationship between plasma risperidone and 9-hydroxyrisperidone concentrations and clinical response in patients with schizophrenia. Psychopharmacology 153:238–243CrossRefPubMedGoogle Scholar
  26. 26.
    Leon J, Susce MT, Pan RM, Wedlund PJ, Orrego ML, Diaz FJ (2007) A study of genetic (CYP2D6 and ABCB1) and environmental (drug inhibitors and inducers) variables that may influence plasma risperidone levels. Pharmacopsychiatry 40:93–102CrossRefPubMedGoogle Scholar
  27. 27.
    Kastelic M, Koprivšek J, Plesničar BK, Serretti A, Mandelli L, Locatelli I, Grabnar I, Dolžan V (2010) MDR1 gene polymorphisms and response to acute risperidone treatment. Prog Neuropsychopharmacol Biol Psychiatry 34:387–392Google Scholar
  28. 28.
    Bozina N, Kuzman MR, Medved V, Jovanovic N, Sertic J, Hotujac L (2008) Associations between MDR1 gene polymorphisms and schizophrenia and therapeutic response to olanzapine in female schizophrenic patients. J Psychiatr Res 42:89–97CrossRefPubMedGoogle Scholar
  29. 29.
    Agid O, Kapur S, Arenovich T, Zipursky RB (2003) Delayed-onset hypothesis of antipsychotic action: a hypothesis tested and rejected. Arch Gen Psychiatry 60:1228–1235CrossRefPubMedGoogle Scholar
  30. 30.
    Leucht S, Busch R, Hamann J, Kissling W, Kane JM (2005) Early-onset hypothesis of antipsychotic drug action: a hypothesis tested, confirmed and extended. Biol Psychiatry 57:1543–1549Google Scholar

Copyright information

© Springer-Verlag 2010

Authors and Affiliations

  • Nikolina Jovanović
    • 1
    Email author
  • Nada Božina
    • 2
  • Mila Lovrić
    • 2
  • Vesna Medved
    • 1
  • Miro Jakovljević
    • 1
  • Alma Mihaljević Peleš
    • 1
  1. 1.Department of Psychiatry, University of Zagreb School of Medicine University Hospital CenterZagrebCroatia
  2. 2.Clinical Institute of Laboratory DiagnosisUniversity Hospital Center ZagrebZagrebCroatia

Personalised recommendations